 ROCKVILLE, Md., Aug. 9, 2021 PRNewswire -- Enrollment in RGX-314 programs is on-track, including the pivotal program for the treatment of wet AMD utilizing subretinal delivery, and the Phase II trials for the treatment of wet AMD and DR utilizing in-office suprachoroidal delivery Interim data from RGX-314 Phase II trial for the treatment of wet AMD utilizing in-office suprachoroidal delivery will be presented at Retina Society 54th Annual Scientific Meeting Reported additional positive interim data in May 2021 from RGX-121 Phase III trial for the treatment of patients up to 5 years old with MPS II; enrollment continues in Cohort 3 at increased dose Expects to file IND for RGX-202 for the treatment of Duchenne by end of 2021 593.0 million in cash, cash equivalents and marketable securities as of June 30, 2021 Conference call Monday, August 9 th at 4:30 p.m. 